Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

Contract Notice

Generic and Biosimilar Cancer Medicines

  • First published: 17 September 2022
  • Last modified: 17 September 2022

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
ocds-h6vhtk-0368ee
Published by:
The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
Authority ID:
AA80495
Publication date:
17 September 2022
Deadline date:
17 October 2022
Notice type:
Contract Notice
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

Supply of Bendamustine Powder For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

Full notice text

Contract notice

Section I: Contracting authority

I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")

Gyle Square (NSS Head Office), 1 South Gyle Crescent

Edinburgh

EH12 9EB

UK

Contact person: Linda Downie

Telephone: +44 1698794410

E-mail: Linda.Downie3@nhs.scot

NUTS: UKM

Internet address(es)

Main address: http://www.nhsscotlandprocurement.scot.nhs.uk/

Address of the buyer profile: http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Generic and Biosimilar Cancer Medicines

Reference number: NP39722

II.1.2) Main CPV code

33600000

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

This Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland.

The Goods have been separated into forty-one (41) categories, each of which is identified as a “Lot”.

Full details of each Lot is contained in section II.2 of this Notice.

II.1.5) Estimated total value

Value excluding VAT: 59 145 973.00  GBP

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

Lot No: 1

II.2.1) Title

Lot 1 Bendamustine Powder For Solution For Infusion

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Bendamustine Powder For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 94 841.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 2

II.2.1) Title

Lot 2 Capecitabine Tablets

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Capecitabine Tablets to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 910 974.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 3

II.2.1) Title

Lot 3 Carboplatin Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Carboplatin Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 596 546.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 4

II.2.1) Title

Lot 4 Cisplatin Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Cisplatin Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 186 020.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 5

II.2.1) Title

Lot 5 Cyclophosphamide Injection, Powder For Reconstitution

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Cyclophosphamide Injection, Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 267 442.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 6

II.2.1) Title

Lot 6 Cytarabine Injections

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Cytarabine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 104 724.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 7

II.2.1) Title

Lot 7 Dacarbazine Injections

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Dacarbazine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 592 972.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 8

II.2.1) Title

Lot 8 Disodium Folinate Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Disodium Folinate Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 442 064.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 9

II.2.1) Title

Lot 9 Docetaxel Concentrate For Solution For Infusion

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Docetaxel Concentrate For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 333 456.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 10

II.2.1) Title

Lot 10 Doxorubicin Hydrochloride Injections

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Doxorubicin Hydrochloride Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 60 002.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 11

II.2.1) Title

Lot 11 Fluorouracil 25MG/ML Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Fluorouracil 25MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 44 750.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 12

II.2.1) Title

Lot 12 Fluorouracil 50MG/ML Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Fluorouracil 50MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 236 261.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 13

II.2.1) Title

Lot 13 Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 108 791.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 14

II.2.1) Title

Lot 14 Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 18 031.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 15

II.2.1) Title

Lot 15 Gemcitabine Powder For Solution For Infusion Vials

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Gemcitabine Powder For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 125 603.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 16

II.2.1) Title

Lot 16 Idarubicin Hydrochlioride Injection Powder For Reconstitution

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Idarubicin Hydrochlioride Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 28 000.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 17

II.2.1) Title

Lot 17 Ifosfamide Injection Powder For Reconstitution

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Ifosfamide Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 2 721 676.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 18

II.2.1) Title

Lot 18 Irinotecan Hydrochloride Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Irinotecan Hydrochloride Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 248 266.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 19

II.2.1) Title

Lot 19 Lanreotide Injection Prefilled Syringes

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Lanreotide Injection Prefilled Syringes to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 4 686 468.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 20

II.2.1) Title

Lot 20 Methotrexate Without Preservatives Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Methotrexate Without Preservatives Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 304 589.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 21

II.2.1) Title

Lot 21 Methotrexate Oral Solution

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Methotrexate Oral Solution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 56 000.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 22

II.2.1) Title

Lot 22 Mitomycin Injection Powder For Reconstitution

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Mitomycin Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 495 141.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 23

II.2.1) Title

Lot 23 Oxaliplatin Vial Solution

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Oxaliplatin Vial Solution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 209 041.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 24

II.2.1) Title

Lot 24 Paclitaxel Concentrate For Intravenous Infusion

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Paclitaxel Concentrate For Intravenous Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 406 689.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 25

II.2.1) Title

Lot 25 Temozolomide Capsules

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Temozolomide Capsules to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 145 833.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 26

II.2.1) Title

Lot 26 Vincristine Without Preservatives Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Description of the procurement

Supply of Vincristine Without Preservatives Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 70 532.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 27

II.2.1) Title

Lot 27 Vinorelbine Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Vinorelbine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 54 400.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 28

II.2.1) Title

Lot 28 Aprepitant Capsules

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Aprepitant Capsules to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 116 097.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 29

II.2.1) Title

Lot 29 Topotecan Capsules

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Topotecan Capsules to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 123 900.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 30

II.2.1) Title

Lot 30 Topotecan Concentrate For Solution For Infusion

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Topotecan Concentrate For Solution For Infusion to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 137 280.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 31

II.2.1) Title

Lot 31 Octreotide Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Octreotide Injection. The Authority intends awarding all presentations within this lot to a single supplier. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 166 600.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 32

II.2.1) Title

Lot 32 Filgrastim Pre-Filled Syringe

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Filgrastim Pre-Filled Syringe to NHS Scotland in a range of presentations. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 1 606 575.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 33

II.2.1) Title

Lot 33 Pemetrexed Powder For Solution For Infusion Vials

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Pemetrexed Powder For Solution For Infusion Vials in various presentations to NHS Scotland.

The Authority intends to award this Lot as a single-supplier framework.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 197 835.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 34

II.2.1) Title

Lot 34 Pemetrexed (25Mg/Ml) Solution For Infusion Vials

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Pemetrexed (25Mg/Ml) Solution For Infusion Vials to NHS Scotland in a range of presentations.

The Authority intends awarding all presentations within this lot to a single supplier.

Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 211 832.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 35

II.2.1) Title

Lot 35 Octreotide Vials Long Acting (Excluding Homecare)

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Octreotide Vials Long Acting (Excluding Homecare) to NHS Scotland. The Authority intends awarding each product line as a multi-supplier unranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 220 850.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

he Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 36

II.2.1) Title

Lot 36 Octreotide Vials Long Acting (Including Homecare)

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Octreotide Vials Long Acting (Including Homecare) to NHS Scotland. The Authority intends awarding each product line as a multi-supplier unranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded. Full details can be found within the ITT.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 1 514 152.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 37

II.2.1) Title

Lot 37 Etoposide Injection

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Etoposide Injection to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier framework to a maximum of three (3) Framework Participants. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 167 904.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 38

II.2.1) Title

Lot 38 Dasatinib Tablets

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of Dasatinib Tablets to NHS Scotland. The Authority intends awarding each product line as a multi-supplier ranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 143 280.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 39

II.2.1) Title

Lot 39 Unranked Multi-Supplier Generic & Biosimilar Medicines

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM


Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Description of the procurement

Supply of a number of Generic & Biosimilar Medicines including bevacizumab solution for infusion, doxorubicin liposomal solution for infusion, rituximab solution for infusion, trastuzumab powder for solution for infusion, sorafenib tablets and thalidomide capsules to NHS Scotland.

Each product line will be treated as an individual Lot and awarded as a unranked multi-supplier to an envisaged maximum of 6 Framework Participants.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 10 529 050.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 40

II.2.1) Title

Lot 40 Idarubicin Hydrochloride Solution for Infusion

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM

II.2.4) Description of the procurement

Supply of Idarubicin Hydrochloride Solution for Infusion.

The Authority intends awarding all presentations within this lot to a single supplier.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 13 114.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 41

II.2.1) Title

Lot 41 Single Supplier Generic Medicines

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKM

II.2.4) Description of the procurement

Supply of a range of generic cancer medicines to NHS Scotland. Each product line will be treated as an individual Lot and awarded to a single Framework Participant.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Award criteria

Criteria below:

Quality criterion: Logistics / Weighting: 5

Price / Weighting:  95

II.2.6) Estimated value

Value excluding VAT: 30 448 391.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 24

This contract is subject to renewal: Yes

Description of renewals:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.3) Technical and professional ability

List and brief description of selection criteria:

(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender.

(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.

(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.

(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.


Minimum level(s) of standards required:

a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.

(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.

(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.

(d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder’s carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions.

III.2) Conditions related to the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement with several operators.

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 17/10/2022

Local time: 12:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date: 17/10/2022

Local time: 12:00

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) Additional information

The estimated value referred to in Section II.I.5 and within each Lot covers the twenty-four (24) months contract duration and the full twenty-four (24) months extension options.

The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 22063. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343

A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363

Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/

A summary of the expected community benefits has been provided as follows:

It is a mandatory requirement that Potential Framework Participants agree to support the concept, provision and ongoing development of community benefits provision in relation to this framework.

Potential Framework Participants are required to agree to this mandatory requirement. They are also requested to provide a brief summary of the community benefits that have recently been delivered within Scotland, if at all, and also what impact and outcomes these have achieved.

Potential Framework Participants are required to summarise any proposed community benefits that will be developed and delivered as part of this contract if successful or, alternatively, Potential Framework Participants confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits.

For further information please visit www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway

(SC Ref:705779)

VI.4) Procedures for review

VI.4.1) Review body

Edinburgh Sheriff Court

Sheriff Court House, 27 Chambers Street

Edinburgh

EH1 1LB

UK

Telephone: +44 1312252525

E-mail: edinburgh@scotcourts.gov.uk

Internet address(es)

URL: https://www.scotcourts.gov.uk/the-courts/court-locations/edinburgh-sheriff-court-and-justice-of-the-peace-court

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures:

The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful. The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

VI.5) Date of dispatch of this notice

16/09/2022

Coding

Commodity categories

ID Title Parent category
33600000 Pharmaceutical products Medical equipments, pharmaceuticals and personal care products

Delivery locations

ID Description
100 UK - All

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

About the buyer

Main contact:
Linda.Downie3@nhs.scot
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.